CT/NG Testing Market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing prevalence of CT/NG infections, increasing investments and funds in CT/NG and growing awareness for diseases diagnosis are driving the growth of this market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=104333528
The key players in this market are
F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN (Netherlands), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Becton, Dickinson and Company (US), Seegene, Inc. (South Korea), Meridian Bioscience Inc. (US), Binx Health, Inc. (US), Visby Medical, Inc. (US), Geneproof A.S. (Czech Republic), Bioneer Corporation (South Korea), Genetic Signatures (Australia), Microbiologics, Inc. (US), Vircell S.L. (Spain), Sansure Biotech Inc. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Operon S.A. (Spain), Tianlong Technology Co., Ltd. (China), and Goffin Molecular Technologies B.V. (Netherlands).
F. Hoffmann-La Roche Ltd. (Switzerland) maintained its dominant position in the CT/NG testing market. The company’s strong distribution networks in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa have contributed to its maintained leadership in the market
Assays & Kits segment is expected to account for the largest share.
Based on product, the CT/NG testing market is segmented into assays & kits and instruments/analyzers. The large share of this segment is due to the recurrent and constant purchase requirement for the diagnosis of various infections and high-burden diseases including sexual health diseases such as CT/NG.
The INAAT segment held the largest market share in the CT/NG testing market.
Based on technology, the CT/NG testing market is broadly segmented into INAAT (isothermal nucleic acid amplification technology), PCR (polymerase chain reaction), immunodiagnostics and other technologies. The INAAT segment accounted for the largest share of the CT/NG testing market.
Inquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=104333528
North America dominates the global CT/NG testing market
North America holds the largest share and expects to dominate the CT/NG testing market. The large share of North America in this market can be attributed to the increasing prevalence of CT/NG, rising advancements in technology, and the growing healthcare system that is highly developed in the US and Canada.
This report categorizes the CT/NG testing market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Assays & Kits
- Instruments/Analyzers
By Testing Type
- Lab Tests
- PoC Tests
By Technology
- Isothermal Nucleic Acid Amplification Technology
- Polymerase Chain Reaction
- Immunodiagnostics
- Other Technologies
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Other End Users
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy This Research Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=104333528
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ctng-testing-market-104333528.html